Abcuro
PrivateLast Round
Series D
Aug 13, 2026
Total Funding Raised
$407.25M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Abcuro is a biotechnology company that develops immunomodulatory therapeutics aimed at treating autoimmunity and cancer through innovative analysis of transcription data to target critical immune system components.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Abcuro Comparables
Compare Abcuro with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Dren Bio | 76% | |
| Kira Biotech Pty Ltd | 74% | |
| Re-Aim Therapeutics | 71% | |
Abcuro Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Aug 13, 2026 | ||||
| Series C | Feb 12, 2025 | ||||
| Series B | Aug 17, 2023 | ||||
| Series A Extension | Jan 7, 2021 | ||||
| Series A | Nov 9, 2018 | ||||
Seed | Dec 13, 2016 |
Key People
Founding team and executive leadership
Abcuro Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Redmile Group | Series C, Series D, Series B |
| Soleus Capital | Series D, Series C, Series B |
| Bain Capital Life Sciences | Series D, Series C, Series B |
| RA Capital Management | Series D, Series C, Series A Extension, Series B |
| New Leaf Venture Partners | Series C, Series B, Series D |
| New Enterprise Associates (NEA) | Series D, Series C |
| Kaitai Capital | Series D, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 13, 2026
Raised $39.4M in early stage VC funding.
- Aug 18, 2025
George Eldridge appointed as new CFO.
Abcuro Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Abcuro's valuation, stock price, and market status.